Exelixis Inc (EXEL)
23.58
+0.06
(+0.23%)
USD |
NASDAQ |
Apr 26, 10:46
Exelixis Enterprise Value: 6.139B for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 6.139B |
| April 24, 2024 | 6.193B |
| April 23, 2024 | 6.066B |
| April 22, 2024 | 5.939B |
| April 19, 2024 | 5.833B |
| April 18, 2024 | 5.824B |
| April 17, 2024 | 5.939B |
| April 16, 2024 | 5.924B |
| April 15, 2024 | 5.887B |
| April 12, 2024 | 5.921B |
| April 11, 2024 | 5.872B |
| April 10, 2024 | 6.184B |
| April 09, 2024 | 6.196B |
| April 08, 2024 | 6.084B |
| April 05, 2024 | 6.021B |
| April 04, 2024 | 6.127B |
| April 03, 2024 | 6.187B |
| April 02, 2024 | 6.081B |
| April 01, 2024 | 6.184B |
| March 28, 2024 | 6.199B |
| March 27, 2024 | 6.239B |
| March 26, 2024 | 6.163B |
| March 25, 2024 | 6.190B |
| March 22, 2024 | 6.215B |
| March 21, 2024 | 6.257B |
| Date | Value |
|---|---|
| March 20, 2024 | 6.193B |
| March 19, 2024 | 6.121B |
| March 18, 2024 | 6.030B |
| March 15, 2024 | 5.972B |
| March 14, 2024 | 5.860B |
| March 13, 2024 | 5.999B |
| March 12, 2024 | 5.884B |
| March 11, 2024 | 5.814B |
| March 08, 2024 | 5.739B |
| March 07, 2024 | 5.702B |
| March 06, 2024 | 5.790B |
| March 05, 2024 | 5.754B |
| March 04, 2024 | 5.842B |
| March 01, 2024 | 5.748B |
| February 29, 2024 | 5.645B |
| February 28, 2024 | 5.648B |
| February 27, 2024 | 5.587B |
| February 26, 2024 | 5.663B |
| February 23, 2024 | 5.532B |
| February 22, 2024 | 5.284B |
| February 21, 2024 | 5.287B |
| February 20, 2024 | 5.260B |
| February 16, 2024 | 5.214B |
| February 15, 2024 | 5.247B |
| February 14, 2024 | 5.187B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
3.278B
Minimum
Oct 10 2022
7.454B
Maximum
May 11 2020
5.139B
Average
5.171B
Median
Jan 21 2020
Enterprise Value Benchmarks
| Regeneron Pharmaceuticals Inc | 88.90B |
| Bristol-Myers Squibb Co | 117.94B |
| Johnson & Johnson | 360.21B |
| Bio-Techne Corp | 10.16B |
| Legend Biotech Corp | 7.053B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 85.52M |
| Revenue (Quarterly) | 479.65M |
| Total Expenses (Quarterly) | 397.86M |
| EPS Diluted (Quarterly) | 0.27 |
| Gross Profit Margin (Quarterly) | 95.46% |
| Profit Margin (Quarterly) | 17.83% |
| Earnings Yield | 2.73% |
| Operating Earnings Yield | 2.25% |
| Normalized Earnings Yield | 2.727 |